8-K: TuHURA Reports Q2 2025 Results, Advances Oncology Pipeline

TuHURA Biosciences reported its second quarter 2025 financial results, highlighting the acquisition of Kineta, initiation of a Phase 3 trial for IFx-2.0, and successful equity financing.

Summary

• Reported financial results for the second quarter ended June 30, 2025, and provided a corporate update.
• Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody, now named TBS-2025.
• Planning to initiate a Phase 2 trial for TBS-2025 in relapsed/refractory NPM1-mutated Acute Myeloid Leukemia (AML) in combination with a menin inhibitor in the second half of 2025.
• Initiated a Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda (pembrolizumab) for first-line advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).
• Initiated a Phase 1b/2a trial employing interventional radiologic administration of IFx-2.0 as an adjunctive therapy to pembrolizumab in first-line treatment of checkpoint-naïve patients with MCC of unknown primary origin (MCCUP).
• Completed a $12.5 million equity financing transaction.
• Received an additional $3.0 million in warrant exercise proceeds from previously disclosed February 2025 warrant exercises.
• Included in the Russell 3000 and Russell 2000 Indexes, effective as of market close on June 27, 2025.
• Research and development expenses were $4.9 million for the three months ended June 30, 2025, compared to $2.8 million for the same period in 2024.
• Net cash outflows from operating activities were ($10.9) million for the six months ended June 30, 2025, compared to ($8.9) million for the same period in 2024.
• Total shares outstanding were approximately 49.9 million as of June 30, 2025.

Sentiment

Score: 8

Explanation: The filing indicates strong operational progress with the initiation of two significant clinical trials, a strategic acquisition expanding the pipeline, and successful capital raises. While R&D expenses and cash burn increased, this is typical for a company advancing multiple late-stage programs. The FDA SPA agreement for the Phase 3 trial is a particularly positive de-risking factor.

Positives

• Successfully completed the acquisition of Kineta, Inc., bolstering the development pipeline with the novel VISTA inhibiting antibody, TBS-2025.
• Initiated a Phase 3 accelerated approval trial for IFx-2.0 in MCC under an FDA Special Protocol Assessment (SPA) agreement, which could lead to both accelerated and full approval without a post-accelerated approval confirmatory trial, saving time and cost.
• Initiated a Phase 1b/2a trial for IFx-2.0 in MCC of unknown primary origin (MCCUP), potentially expanding the commercial market opportunity by addressing approximately 30% of newly diagnosed advanced or metastatic MCC cases.
• Strengthened financial position by completing a $12.5 million equity financing transaction and receiving an additional $3.0 million from warrant exercises.
• Enhanced market visibility and liquidity through inclusion in the Russell 3000 and Russell 2000 Indexes.

Negatives

• Research and development expenses increased to $4.9 million in Q2 2025 from $2.8 million in Q2 2024, indicating higher operational costs.
• Net cash outflows from operating activities increased to ($10.9) million in H1 2025 from ($8.9) million in H1 2024, reflecting increased cash burn.

Risks

• Forward-looking statements are not guarantees of future performance, and actual results or developments may differ materially from those set forth in these statements.
• Factors that could cause actual results to differ materially are described in detail in SEC registration statements, reports, and other filings.

Future Outlook

TuHURA anticipates providing an update on enrollment progress for its Phase 3 IFx-2.0 trial by year-end 2025. Topline results from the Phase 1b/2a MCCUP trial are expected in Q1 2026, and from the Phase 3 accelerated approval trial in 2H 2026. The company also plans to initiate a Phase 2 trial for TBS-2025 in AML in 2H 2025 and present non-clinical data for its APC and ADC development candidates at relevant medical meetings in 2025.

Management Comments

• "TuHURA had a strong first-half of the year with the initiation of its Phase 3 accelerated approval trial of IFx-2.0 as an adjunctive therapy to pembrolizumab as a first line treatment for patients with advanced or metastatic MCC."
• "Conducted under an SPA Agreement with the FDA, the Phase 3 trial is a single randomized placebo-controlled trial that, if successful, has the potential to both meet and satisfy the requirements for both accelerated and full approval without the need to conduct a post-accelerated approval confirmatory trial. This potentially translates to a meaningful time and cost savings to TuHURA." James Bianco, M.D., President and Chief Executive Officer
• "Patients with MCCUP represent approximately a thirty percent (30%) of all newly diagnosed advanced or metastatic MCC cases and can meaningfully augment IFx-2.0s commercial market opportunity." James Bianco, M.D., President and Chief Executive Officer
• "In addition to our trial initiations in MCC and MCCUP, we recently bolstered our development pipeline with the acquisition of Kineta and their novel VISTA inhibiting antibody, TBS-2025. The acquisition provides for synergies across both TuHURAs therapeutic focus as well as TuHURAs antibody peptide or drug candidate (APC, ADC) technologies as we continue to assemble a diversified, late-stage immuno-oncology pipeline." James Bianco, M.D., President and Chief Executive Officer

Industry Context

TuHURA Biosciences operates in the highly competitive immuno-oncology sector, focusing on developing novel technologies to overcome resistance to cancer immunotherapy. The acquisition of Kineta and its VISTA inhibiting antibody, TBS-2025, diversifies its late-stage pipeline, aligning with the industry trend of exploring combination therapies to enhance the efficacy of existing treatments like checkpoint inhibitors. The company's strategic focus on Merkel cell carcinoma (MCC) and Acute Myeloid Leukemia (AML) addresses specific unmet medical needs within oncology, positioning it to potentially capture significant market share in these areas.

Comparison to Industry Standards

• The initiation of a Phase 3 accelerated approval trial for IFx-2.0 under an FDA Special Protocol Assessment (SPA) agreement is a significant de-risking event, as SPA agreements provide a clear regulatory pathway and can expedite approval, a competitive advantage compared to companies without such agreements.
• The planned Phase 2 trial of TBS-2025 in combination with a menin inhibitor for NPM1-mutated AML positions TuHURA to compete with other companies developing therapies for this indication, such as Syndax Pharmaceuticals with its menin inhibitor revumenib, by exploring synergistic treatment approaches.
• Expanding the IFx-2.0 program to include MCC of unknown primary origin (MCCUP) aims to capture an additional 30% of the advanced/metastatic MCC market, a strategy common among oncology companies seeking to maximize the commercial potential of their lead assets by broadening indications.

Stakeholder Impact

• Shareholders: Potential for increased value due to pipeline advancement, successful capital raise, and inclusion in Russell indexes, balanced against potential dilution from equity financing.
• Patients: Potential for new and improved treatment options for advanced/metastatic MCC and relapsed/refractory NPM1-mutated AML.
• Employees: Continued employment and potential growth opportunities as the company advances its clinical programs and expands its pipeline.
• Regulatory Authorities (FDA): Ongoing collaboration and adherence to regulatory pathways through the SPA agreement for the IFx-2.0 trial.

Next Steps

• Provide an update on enrollment progress in Phase 3 accelerated approval trial of IFx-2.0 by Year-End 2025.
• Anticipate topline results from Phase 1b/2a clinical trial of IFx-2.0 in MCCUP in Q1 2026.
• Anticipate topline results from Phase 3 accelerated approval trial of IFx-2.0 in 2H 2026.
• Planned initiation of Phase 2 trial of TBS-2025 in AML in 2H 2025.
• Present non-clinical data for APC and ADC development candidates at relevant medical meetings in 2025.

Key Dates

Recommendation

The company has made significant clinical and strategic progress, including initiating a pivotal Phase 3 trial with an FDA SPA agreement, acquiring a promising new asset (TBS-2025) for AML, and successfully raising capital to fund these initiatives. The SPA agreement significantly de-risks the IFx-2.0 program by providing a clear regulatory path. The expansion into MCCUP and AML broadens the market opportunity. While cash burn is increasing, it is commensurate with advancing late-stage clinical programs. These developments suggest strong future growth potential and a positive outlook for the stock.

Keywords

Immuno-oncology, Cancer immunotherapy, Merkel cell carcinoma, Acute Myeloid Leukemia, AML, VISTA inhibitor, Keytruda, Pembrolizumab, Clinical trials, Phase 3, Phase 2, Drug development, Biotechnology, NASDAQ:HURA, Kineta, TBS-2025, IFx-2.0, Delta Opioid Receptor, Antibody drug conjugate, Antibody peptide conjugate